| Phase 12 trials |
|
Phase 1
|
NCT06116240 |
Sep 2022 → Dec 2023 |
cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT02779699 |
May 2016 → Oct 2020 |
— |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT05745363 |
Feb 2023 → Nov 2025 |
differentiated thyroid carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT05011019 |
Sep 2021 → Feb 2024 |
malignant peripheral nerve sheath tumor |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 1/2
|
NCT04337879 |
Jul → Dec 2020 |
colorectal cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT06278493 |
Aug 2018 → Oct 2021 |
malignant pancreatic neoplasm |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT05815862 |
Feb 2023 → Aug 2025 |
lung cancer, ovarian cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04325776 |
Sep 2020 → May 2021 |
non-small cell lung carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT06860971 |
Apr 2025 → Jan 2027 expected |
thyroid cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05922345 |
Jun 2023 → Aug 2025 |
non-small cell lung carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|